Phase I
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
NGM Bio’s aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
It was another busy week for clinical trial announcement. Here’s a look.
“The virus will not be eradicated through vaccination alone. That means... we need our medicines. That was a failure of 2020 that doesn’t get enough emphasis,” Jake Glanville, chief executive officer of Bay Area-based Centivax, told BioSpace in an interview.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
Sarepta Therapeutics announced its gene therapy candidate, SRP-9001, shows “robust expression and consistent safety profile.”
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
PRESS RELEASES